Long-Term Efficacy and Safety of Enzalutamide Monotherapy in Elderly Patients with Metastatic Castration-Resistant Prostate Cancer: A Case Report.

Pokrivcak, Tomas; Navratil, Jiri; Poprach, Alexandr; Stanik, Michal; Kiss, Igor

Pokrivcak, Tomas; Navratil, Jiri; Poprach, Alexandr; Stanik, Michal; Kiss, Igor.

Afiliación

Pokrivcak T; Masaryk Memorial Cancer Institute, Brno, Czech Republic.
Navratil J; Faculty of Medicine, Masaryk University, Brno, Czech Republic.
Poprach A; Masaryk Memorial Cancer Institute, Brno, Czech Republic.
Stanik M; Faculty of Medicine, Masaryk University, Brno, Czech Republic.
Kiss I; Masaryk Memorial Cancer Institute, Brno, Czech Republic.

Case Rep Oncol ; 17(1): 537-542, 2024.

Article en En | MEDLINE | ID: mdl-38577248

ABSTRACT

ABSTRACT

Introduction:

Prostate cancer is one of the most common cancers in men. Despite the sharp rise in incidence, mortality is decreasing. ARTA preparations are preferred options for asymptomatic or mildly symptomatic patients with mCRPC. The use of enzalutamide in elderly patients with mCRPC is risky and depends on a number of factors. An increased risk of falls and fractures has been shown. Case Presentation We present a case report of an elderly patient with mCRPC treated with enzalutamide with very good long-term tolerance and efficacy.

Conclusion:

Despite the older age, no reduction of therapy was necessary in the patient due to good tolerance. Administration of enzalutamide in full doses resulted in a very good effect of therapy.

Palabras clave

Aged 75 and over; Comorbidity; Enzalutamide; Metastatic castration-resistant prostate cancer

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Case Rep Oncol Año: 2024 Tipo del documento: Article País de afiliación: República Checa Pais de publicación: Suiza

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google